PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 561-566

  Postmus, Iris ^a,b   Trompet, Stella ^a,b   De Craen, Anton J M ^a,b   Buckley, Brendan M ^c   Ford, Ian ^d   Stott, David J ^d   Sattar, Naveed ^e   Slagboom, P Eline ^a,b   Westendorp, Rudi G J ^a,b,f   Jukem, J Wouter ^a,g,h  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Ageing   (Netherlands)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f Leyden Academy of Vitality and Ageing   (Netherlands)

^g Durrer Center for Cardiogenetic Research   (Netherlands)

^h ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Genetic variation; Lipid lowering; PROSPER; Single nucleotide polymorphism

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DAILY LIFE ACTIVITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL PERFORMANCE; POPULATION RISK; PRIORITY JOURNAL; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9 GENE; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVITIES OF DAILY LIVING; AGED; CHOLESTEROL, LDL; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; VASCULAR DISEASES;

EID: 84872473017     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P033969     Document Type: Article

References (24)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 106: 3143-3421.
2. Brautbar, A., and C. M. Ballantyne. 2011. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 8: 253-265.
3. Cariou, B., M. C. Le, and P. Costet. 2011. Clinical aspects of PCSK9. Atherosclerosis. 216: 258-265.
4. Tibolla, G., G. D. Norata, R. Artali, F. Meneghetti, and A. L. Catapano. 2011. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr. Metab. Cardiovasc. Dis. 21: 835-843.
5. Lambert, G., M. Krempf, and P. Costet. 2006. PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol. Metab. 17: 79-81.
6. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94: 2537-2543.
7. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
8. Folsom, A. R., J. M. Peacock, and E. Boerwinkle. 2009. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis. 202: 211-215.
9. Benn, M., B. G. Nordestgaard, P. Grande, P. Schnohr, and A. Tybjaerg-Hansen. 2010. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J. Am. Coll. Cardiol. 55: 2833-2842.
10. Bélanger Jasmin, S. 2011. A putative role for PCSK9 in synaptic remodelling and plasticity in response to brain injury: implications for Alzheimer's disease. McGill University (http://digitool.library.mcgill.ca/ webclient/StreamGate?folder-id=0&dvs=1352716244239~284) 59-83
11. Trompet, S., P. van Vliet, A. J. de Craen, J. Jolles, B. M. Buckley, M. B. Murphy, I. Ford, P. W. Macfarlane, N. Sattar, C. J. Packard, et al. 2010. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J. Neurol. 257: 85-90.
12. van Vliet, P., W. van de Water, A. J. de Craen, and R. G. Westendorp. 2009. The influence of age on the association between cholesterol and cognitive function. Exp. Gerontol. 44: 112-122.
13. Shepherd, J., G. J. Blauw, M. B. Murphy, S. M. Cobbe, E. L. Bollen, B. M. Buckley, I. Ford, J. W. Jukema, M. Hyland, A. Gaw, et al. 1999. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am. J. Cardiol. 84: 1192-1197. (Pubitemid 29507501)
14. Shepherd, J., G. J. Blauw, M. B. Murphy, E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, et al. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360: 1623-1630. (Pubitemid 35379733)
15. Houx, P. J., J. Shepherd, G. J. Blauw, M. B. Murphy, I. Ford, E. L. Bollen, B. Buckley, D. J. Stott, W. Jukema, M. Hyland, et al. 2002. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J. Neurol. Neurosurg. Psychiatry. 73: 385-389.
16. Polisecki, E., I. Peter, M. Robertson, A. D. McMahon, I. Ford, C. Packard, J. Shepherd, J. W. Jukema, G. J. Blauw, R. G. Westendorp, et al. 2008. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis. 200: 95-101.
17. Havekes, L. M., P. de Knijff, U. Beisiegel, J. Havinga, M. Smit, and E. Klasen. 1987. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J. Lipid Res. 28: 455-463. (Pubitemid 17055558)
18. Trompet, S., A. J. de Craen, I. Postmus, I. Ford, N. Sattar, M. Caslake, D. J. Stott, B. M. Buckley, F. Sacks, J. J. Devlin, et al. 2011. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Med. Genet. 12: 131.
19. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81: 559-575. (Pubitemid 47330214)
20. Shibata, N., T. Ohnuma, S. Higashi, M. Higashi, C. Usui, T. Ohkubo, T. Watanabe, R. Kawashima, A. Kitajima, A. Ueki, et al. 2005. No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients. Psychiatr. Genet. 15: 239. (Pubitemid 44491460)
21. Stein, E. A., D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, R. Dufour, R. Wu, and R. Pordy. 2012. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 380: 29-36.
22. McKenney, J. M., M. J. Koren, D. J. Kereiakes, C. Hanotin, A. C. Ferrand, and E. A. Stein. 2012. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59: 2344-2353.
23. Kohli, P., N. R. Desai, R. P. Giugliano, J. B. Kim, R. Somaratne, F. Huang, B. Knusel, S. McDonald, T. Abrahamsen, S. M. Wasserman, et al. 2012. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin. Cardiol. 35: 385-391.
24. Packard, C. J., R. G. Westendorp, D. J. Stott, M. J. Caslake, H. M. Murray, J. Shepherd, G. J. Blauw, M. B. Murphy, E. L. Bollen, B. M. Buckley, et al. 2007. Association between apolipoprotein E4 and cognitive decline in elderly adults. J. Am. Geriatr. Soc. 55: 1777-1785. (Pubitemid 350043781)